Cemsidomide demonstrated a 50% ORR at 100 μg, with one patient achieving a complete response and no detectable disease. The phase 1 study's dose-escalation phase is complete, and the 100 μg dose is ...
Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune system ...
Results showed that patients treated with IberDd demonstrated a statistically significant improvement in MRD negativity rates vs those treated with DVd. Topline data were announced from a phase 3 ...
Equecabtagene autoleucel showed high efficacy in relapsed/refractory multiple myeloma, with a 96% overall response rate and 42.6% complete response rate at three months. Minimal residual disease ...
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein ...
The management of treatment side effects can expand caregiver duties significantly, and can involve working more closely with ...
Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease from universally fatal to curable for a substantial proportion of patients.
Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- ...
ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) The randomized, open-label, ...
Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results